[HTML][HTML] CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
R Velasco, A Mussetti, M Villagrán-García… - Frontiers in …, 2023 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell systemic immunotherapy has revolutionized how
clinicians treat several refractory and relapsed hematologic malignancies. Due to its peculiar …
clinicians treat several refractory and relapsed hematologic malignancies. Due to its peculiar …
[HTML][HTML] Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies
CB García-Calderón, B Sierro-Martínez… - Frontiers in …, 2023 - frontiersin.org
Purpose CAR-T cell therapy has proven to be a disruptive treatment in the hematology field,
however, less than 50% of patients maintain long-term response and early predictors of …
however, less than 50% of patients maintain long-term response and early predictors of …